IDO1 and neoplasm: In a murine model of breast cancer, siRNA-mediated silencing of IDO in vaccinating DC enhanced the ability of these cells to stimulate T cell proliferation and CTL effector function, decreased the induction of CD4+ CD25+ FOXP3+ Tregs, and led to enhanced control of tumor outgrowth (159).